A modified high‐dose dexamethasone regimen for primary systemic (AL) amyloidosis
Open Access
- 1 June 2001
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 113 (4) , 1044-1046
- https://doi.org/10.1046/j.1365-2141.2001.02859.x
Abstract
The British Journal of Haematology publishes original research papers in clinical, laboratory and experimental haematology. The Journal also features annotations, reviews, short reports, images in haematology and Letters to the Editor.Keywords
This publication has 8 references indexed in Scilit:
- Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapyBlood, 2000
- Phase II trial of high-dose dexamethasone for untreated patients with primary systemic amyloidosisMedical Oncology, 1999
- Phase II trial of high-dose dexamethasone for previously treated immunoglobulin light-chain amyloidosisAmerican Journal of Hematology, 1999
- Dexamethasone induces apoptosis of multiple myeloma cells in a JNK/SAP kinase independent mechanismOncogene, 1997
- A Trial of Three Regimens for Primary Amyloidosis: Colchicine Alone, Melphalan and Prednisone, and Melphalan, Prednisone, and ColchicineNew England Journal of Medicine, 1997
- Treatment of AL-Amyloidosis with Dexamethasone Plus Alpha InterferonLeukemia & Lymphoma, 1997
- Phase II trial of recombinant interferon alfa‐2 in the treatment of primary systemic amyloidosisAmerican Journal of Hematology, 1993
- Primary dexamethasone treatment of multiple myelomaBlood, 1992